Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in Non-cystic Fibrosis Bronchiectasis
NCT03988816Phase 2Unknown
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Non-cystic fibrosis bronchiectasis (NCFB) comparing Roflumilast with Placebo (2 arms). Primary endpoint: Quality of life questionnaire at 12 weeks. Status: unknown.
02
Drugs
roflumilast
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT03988816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988816.